Tarsons Products
Tarsons Products Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Demand for plastic labware products in the domestic market has begun to pick up with increased order inflows. Revenue growth expected to strengthen in FY '27 and beyond due to capacity expansion, steady demand, and new product scale-up. - Volume-led growth anticipated despite moderate pricing pressure from competition. - EBITDA margins likely to improve as new capacities, especially Panchla facility, ramp up (breakeven expected at ~INR 70-75 crores revenue). - Adjusted PAT and cash PAT showed strong growth in Q3 and 9-months FY '26, indicating robust profitability trends. - Long-term scale-up in new segments like cell culture and bioprocessing expected over 3-4 years, contributing to revenue and margin expansion. - International market growth, fueled by recent India-U.S.
From Tarsons Products's Q3 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Demand for plastic labware products in the domestic market has begun to pick up with increased order inflows.
- Operating near full capacity in existing plants, with efforts to expedite new capacity ramp-up, aiming for stronger revenue growth in FY '27 and beyond.
- Introduction of new product categories from recent capex to expand overall addressable market and drive incremental sales.
- Export markets expected to lead growth initially, supported by tariff reductions via India-EU and India-US FTAs, improving competitiveness internationally.
- Gradual scale-up expected over 2-3 years for new products, reaching near optimal capacity in about 3-4 years.
- Leveraging overseas subsidiary Nerbe and expanded product portfolio to grow presence in Europe and other international geographies.
2 more points from Tarsons Products's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Tarsons Products said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Tarsons has undertaken a significant capex of INR 600 crores announced in 2021-22, with partial commercialization in 2026.
- About 70% of this capex focused on new product development and land/building, with 25-30% on capacity expansion.
- Bioprocess product facilities are commissioned but underutilized; full capacity could generate over INR 150 crores in revenue.
- Break-even expected at around INR 70-75 crores revenue for the Panchla facility.
- Cell culture capex coming online in Q4; will require sampling and scale-up over 2-3 years to reach optimal capacity (15-20% in year 1, 30-35% by year 2).
2 more points from Tarsons Products's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tarsons Products said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Tarsons Products's call on order book
Pro opens every point from 15K+ earnings calls
Tarsons Products — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹121 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tarsons Products Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- QMS Medical Allied Services Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹37.3 crore . Key investor presentation takeaways from QMS Medical Allied Services Ltd's Q3 FY26 investor presentation — and how
- Laxmi Dental Ltd (Q3 FY26)
Scanner sales growth to continue, with digital penetration in India planned to increase from 79% to 90%, driving future expansion. Key concall takeaways from…
Arthneeti Pro · Annual
Tarsons Products and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Tarsons Products Q3 FY26 results?
Demand for plastic labware products in the domestic market has begun to pick up with increased order inflows. Revenue growth expected to strengthen in FY '27 and beyond due to capacity expansion, steady demand, and new product scale-up. - Volume-led growth anticipated despite moderate pricing pressure from competition. - EBITDA margins likely to improve as new capacities, especially Panchla facility, ramp up (breakeven expected at ~INR 70-75 crores revenue). - Adjusted PAT and cash PAT showed strong growth in Q3 and 9-months FY '26, indicating robust profitability trends. - Long-term scale-up in new segments like cell culture and bioprocessing expected over 3-4 years, contributing to revenue and margin expansion. - International market growth, fueled by recent India-U.S.
What is Tarsons Products share price analysis?
Tarsons Products currently shows a neutral. The stock trades at a P/E of 155.0 with a market cap of ₹1,835 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tarsons Products planning capital expenditure?
Tarsons has undertaken a significant capex of INR 600 crores announced in 2021-22, with partial commercialization in 2026.
Keep Tarsons Products on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.